Sosei Heptares Webinar Presentation for FY2023 Financial Results
22 janv. 2024 04h30 HE
|
Sosei Group Corporation
Tokyo, Japan and Cambridge, UK, 22 January 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) will announce its earnings results and present operational highlights for the...
Sosei Group Announces Appointment of Experienced Pharmaceutical Executive Toshihiro Maeda as Chief Operating Officer
05 janv. 2024 03h00 HE
|
Sosei Group Corporation
Tokyo, Japan and Cambridge, UK, 5 January 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) today announces the appointment of Mr. Toshihiro Maeda as Chief Operating...
Sosei Heptares to Present at 42nd Annual J.P. Morgan Healthcare Conference
21 déc. 2023 03h23 HE
|
Sosei Group Corporation
Tokyo, Japan and Cambridge, UK, 21 December 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565), announces its President & CEO, Chris Cargill, will present at the 42nd...
Sosei Group Announces Marketing Approval for PIVLAZ™ (clazosentan sodium) 150 mg in South Korea
07 déc. 2023 01h35 HE
|
Sosei Group Corporation
PIVLAZ™, a new drug for prevention of Cerebral Vasospasm in patients with Aneurysmal Subarachnoid Hemorrhage (aSAH), approved in South KoreaPIVLAZ will become commercially available in South Korea in...
Sosei Heptares’ Partner Neurocrine Biosciences Confirms its Plans to Evaluate Two New Muscarinic Agonist Candidates in Phase 1 Clinical Studies
06 déc. 2023 03h01 HE
|
Sosei Group Corporation
Both NBI-1117569 (an M4-preferring agonist) and NBI-1117567 (an M1-preferring agonist) are investigational, oral, muscarinic agonists discovered by Sosei Heptares that may have the potential to treat...
Sosei Heptares to Regain Full Ownership of GSK4381406*, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease
24 nov. 2023 03h35 HE
|
Sosei Group Corporation
GPR35 is a novel target with an established genetic association to IBDUK regulatory approval received to commence first-in-human studiesIndependent commercial analysis supports a worldwide peak sales...
Sosei Heptares and Kallyope Nominate First GPCR Target for Therapeutic Development in Gastrointestinal Diseases
10 nov. 2023 01h35 HE
|
Sosei Group Corporation
Tokyo, Japan, Cambridge, UK and New York, USA – 10 November 2023 – Sosei Group Corporation (“Sosei Heptares”; TSE: 4565), the international biopharmaceutical company, and Kallyope, a clinical stage...
Sosei Heptares Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2023
10 nov. 2023 01h30 HE
|
Sosei Group Corporation
Tokyo, Japan and Cambridge, UK, 10 November 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated...
Sosei Heptares’ President & CEO and Head of UK R&D to Participate in a ‘Fireside Chat’ at the Jefferies London Healthcare Conference 2023
07 nov. 2023 04h00 HE
|
Sosei Group Corporation
Tokyo, Japan and Cambridge, UK, 7 November 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) announces its President & CEO, Chris Cargill, and Matt Barnes, Head of UK...
Sosei Heptares’ Partner, Pfizer, Progresses Its GLP-1 Receptor Agonist PF-06954522 into a Phase 1 Trial
05 nov. 2023 18h35 HE
|
Sosei Group Corporation
PF-06954522 was introduced into Pfizer’s Internal Medicine focused clinical pipeline as part of its Q3 2023 results presentation Tokyo, Japan and Cambridge, UK, 06 November 2023 – Sosei Group...